Which company developed Utebzi?

GSK (GlaxoSmithKline) developed Utebzi.

How is Utebzi different from other treatments?

Utebzi is the first oral carbapenem, offering a convenient alternative to intravenous therapies.

When will Utebzi be available?

GSK has not announced a launch date yet; it will require a prescription.

Who are the main competitors of Utebzi?

Competitors include Merck's Zerbaxa and Pfizer's Avycaz.

GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections

GSK received FDA approval for Utebzi, the first oral carbapenem antibiotic for complicated urinary tract infections (cUTI). This launch strengthens GSK's anti-infectives pipeline.

June 18, 2026

1 min read

Source: Zacks

GSK has secured FDA approval for its new drug Utebzi, the first oral carbapenem antibiotic indicated for complicated urinary tract infections (cUTI).

The Product

Utebzi is an oral carbapenem antibiotic, offering a convenient alternative to intravenous therapies. It targets a broad spectrum of multidrug-resistant bacteria, addressing an unmet medical need.

Pricing and Availability

GSK has not yet disclosed Utebzi's pricing or launch timeline. It is expected to be available by prescription following logistical arrangements.

Competition

Utebzi competes with other cUTI treatments such as Merck's Zerbaxa and Pfizer's Avycaz, but its oral carbapenem class gives it a unique edge.

Potential Impact on GSK

Utebzi is expected to boost GSK's anti-infectives revenue amid rising antibiotic resistance. This launch may also impact market share of competitors like Merck (MRK) and Pfizer (PFE).

Frequently Asked Questions

Utebzi is the first oral carbapenem antibiotic approved by the FDA for complicated urinary tract infections.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.